SynbiCITE 2.0

  • Funded by UK Research and Innovation (UKRI)
  • Total publications:11 publications

Grant number: EP/S001859/1

Grant search

Key facts

  • Disease

  • Start & end year

  • Known Financial Commitments (USD)

  • Funder

    UK Research and Innovation (UKRI)
  • Principle Investigator

  • Research Location

    United Kingdom, Europe
  • Lead Research Institution

    Imperial College London
  • Research Category

    Pathogen: natural history, transmission and diagnostics

  • Research Subcategory


  • Special Interest Tags


  • Study Subject


  • Clinical Trial Details


  • Broad Policy Alignment


  • Age Group

    Not Applicable

  • Vulnerable Population

    Not applicable

  • Occupations of Interest

    Not applicable


Synthetic biology workflows drive higher throughput testing. The approach, led by SynbiCITE Co-Director Professor Paul Freemont, originates from the flexible and adaptable nature of automated synthetic biology workflows. Using the 'design, build, test, learn' approach that is fundamental to synthetic biology, Professor Freemont and a team from the Dementia Research Institute and Imperial College London, used the London BioFoundry's Felix robots to design new workflows to carry out COVID-19 antigen testing using the standard PCR.

Publicationslinked via Europe PMC

Last Updated:41 minutes ago

View all publications at Europe PMC

Removing the Bottleneck: Introducing cMatch - A Lightweight Tool for Construct-Matching in Synthetic Biology.

PASIV: A Pooled Approach-Based Workflow to Overcome Toxicity-Induced Design of Experiments Failures and Inefficiencies.

Synthetic biology and bioelectrochemical tools for electrogenetic system engineering.

Correction to: Refactoring of a synthetic raspberry ketone pathway with EcoFlex.

Building the UK's industrial base in engineering biology.

Addressing the post‐COVID era through engineering biology

Build a Sustainable Vaccines Industry with Synthetic Biology.

Engineering Microbiomes-Looking Ahead.

A role for Biofoundries in rapid development and validation of automated SARS-CoV-2 clinical diagnostics.